MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer

Pancreatic Cancer Clinical Trial

Official title:

Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05076760
• Other study ID #: CCI-2003
• Status: Recruiting
• Phase: Phase 1
• Start date: February 23, 2022
• Est. completion date: November 2026

Study information

• Verified date: February 2024
• Source: Memgen, Inc.
• Contact: Mark J. Cantwell, PhD
• Phone: 858-869-1477
• Email: mcantwell[@]memgenbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial is designed in two parts. First as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is accessible for injection will undergo intratumoral injection of MEM-288. Following completion of the monotherapy study portion of the study, an expansion arm is designed to test MEM-288 with concurrent anti-PD-1 (nivolumab) therapy for patients with first relapsed or refractory advanced/metastatic NSCLC following front-line anti-PD-1/PD-L1 with or without concurrent chemotherapy. The study rationale is that the oncolytic effect of MEM-288 combined with the presence of CD40L and type 1 interferon (IFN) in injected tumors will provide a strong signal for dendritic cell (DC)-mediated T cell activation leading to generation of systemic anti-tumor T cell responses with broad specificity akin to what is observed in the abscopal effect. Further study rationale is the anti-tumor effect of MEM-288 will be enhanced by nivolumab by reversing T cell exhaustion.

Description:

MEM-288 is a conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40). MEM-288 was developed as an immunotherapy for cancer and was engineered to selectively replicate in cancer cells leading to cancer cell lysis but not cytotoxicity towards normal cells. Simultaneously, MEM-288 is designed to stimulate an anti-tumor immune response through expression of its encoded immune agonist transgenes. MEM-288 is designed to provide both antitumor activity as a standalone monotherapy and in combination with immune checkpoint inhibitor(s) to enhance the efficacy of immune checkpoint inhibition in solid tumors. This phase I trial will be conducted in two parts. The first part is an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the MTD and recommended phase II dose for the planned combination of MEM-288 with an immune checkpoint inhibitor. Patients (≥ 18 years old) eligible for study enrollment include those with either advanced/metastatic NSCLC, cutaneous squamous-cell carcinoma (cSCC), Merkel cell, melanoma, triple negative breast cancer (TNBC), pancreatic cancer, or head and neck cancer, who progressed following previous anti-PD-1/PD-L1 therapy, with a tumor lesion which is accessible for injection. The primary study objective of the monotherapy dose escalation portion of the study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of intratumoral administration of MEM-288 as a single agent. Secondary objectives will assess efficacy overall response rate, as well as disease control rate, progression free survival, duration of response, and anti-tumor immune responses. The second part of the phase 1 trial is an expansion arm designed to test MEM-288 with concurrent anti-PD-1 (nivolumab) therapy for patients with first relapsed or refractory advanced/metastatic NSCLC following front-line anti-PD-1/PD-L1 with or without concurrent chemotherapy. The primary study objective of the combination portion of the study is to determine the overall response rate of the combination of MEM-288 plus nivolumab in patients with advanced recurrent/metastatic NSCLC. Secondary objectives will assess the safety and tolerability of MEM-288 plus nivolumab, as well as disease control rate, progression free survival, duration of response, and anti-tumor immune responses. MEM-288 will be administered via intratumoral injection once every 3 weeks (planned 2 doses, maximum 6 doses) at an assigned dose cohort level (from 1x10^10 to 1x10^11 viral particles) for the monotherapy portion of the study. For the combination portion of the study, MEM-288 will be administered via intratumoral injection once every 3 weeks (planned 2 doses, maximum 6 doses) at an assigned dose total dose of 1x10^11 viral particles. MEM-288 may be injected in multiple lesions until the maximum injection dose (1x10^11 viral particles) is reached. Nivolumab will be administered at a dose of 360 mg via intravenous infusion once every 3 weeks, with optional maintenance nivolumab therapy every 3 weeks for up to 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 61
• Est. completion date: November 2026
• Est. primary completion date: November 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ability to understand and provide informed consent.

2. Willingness and ability to comply with scheduled study visits and procedures.

3. Adult men or women age = 18 years.

4. ECOG performance status of 0 or 1.

5. Part 1 monotherapy: Advanced/metastatic NSCLC, cSCC, Merkel cell, melanoma, TNBC, pancreatic cancer, or head and neck cancer.

6. Part 2 MEM-288 plus nivolumab combination: Advanced/metastatic NSCLC which has progressed following front-line anti-PD-1/PD-L1 with or without concurrent chemotherapy. No more than one prior line of therapy for advanced/metastatic disease.

7. Per each tumor type shown below, the specific initial standard of care therapies after which the subjects with specific histologies must have progressed have been included. Subjects will have been treated with at least one or more than one line of therapy prior to enrollment in the study.

1. Non-small cell lung cancer (NSCLC) Part 1 monotherapy

• Must have progressed on standard therapy, including platinum-based chemotherapy and checkpoint inhibitor therapy (combined or sequential).
• Patients with tumors that have known actionable molecular alteration such in EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS must have progressed on standard directed molecular therapy, and platinum-based chemotherapy. Part 2 MEM-288 plus nivolumab combination
• Must have first progression more than (>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or PD-L1 checkpoint inhibitor therapy with or without concurrent chemotherapy

2. Cutaneous squamous-cell carcinoma (cSCC)

• Must have progressed on standard therapy, including platinum-based chemotherapy and/or checkpoint inhibitor therapy.

3. Merkel cell Carcinoma

• Must have progressed on standard checkpoint inhibitor therapy.

4. Melanoma

• Subjects must have received a BRAF inhibitor as monotherapy or in combination with other targeted agents for BRAF V600E mutant melanoma.
• Subjects must have received an anti-PD-1/ PD-L1inhibitor as monotherapy or combination with anti-CTLA-4 inhibitor or other therapies.

5. Pancreatic cancer

• Progression after systemic chemotherapy which included either gemcitabine or Fluorouracil (5-FU)-based regimen (including capecitabine).

6. Triple negative breast cancer (TNBC)

• Prior treatment (for advanced, metastatic or (neo)adjuvant) must have included a taxane and/or anthracycline-based therapy.

7. Head and Neck Cancer

• Prior treatment requirement in the metastatic or unresectable locally

advanced setting include:

• Subjects must have received a platinum containing chemotherapy regimen for treatment of primary tumor in locally advanced, or metastatic settings
• Subjects must have received an anti-PD-1/ PD-L1 as monotherapy or in combination with chemotherapy.

8. Progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status), except for patients with pancreatic cancer. a) Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression).

9. Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, must have been previously treated with an applicable tyrosine kinase inhibitor.

10. Tumor lesion which is deemed feasible for biopsy and injection under CT or ultrasound guidance (based on size, location, and visibility) by an interventional radiologist, and patient willing and able to provide tissue from biopsy of this lesion. Injected tumor should be > 1 cm3 in volume and should not encase or be inseparable from vital structures such as major nerves or blood vessels. a) For Part 1 monotherapy patients treated at the first dose level, the tumor for injection must be an accessible cutaneous, subcutaneous, or superficial lymph node lesion that is palpable.

11. Measurable disease, as defined per RECIST version 1.1.

12. Prior history of brain metastases are eligible, provided:

1. Brain metastases have been treated

2. Asymptomatic from the brain metastases

3. Corticosteroids prescribed for the management of brain metastases have been discontinued at least 7 days before registration to study

4. Brain metastases are stable on pre-registration imaging

5. No evidence of leptomeningeal disease

13. Life expectancy > 3 months.

14. Adequate organ and marrow function as defined below:

1. Absolute neutrophil count (ANC) =1.5 x 10^9/L

2. Hemoglobin =90 g/L (or =9 g/dL)

3. Platelets =100 x 10^9/L

4. Calculated creatinine clearance of >50 mL/min using Cockcroft Gault equation

5. Total bilirubin = 1.5 x institutional upper limit of normal

6. AST (SGOT) and ALT (SGPT) =2.5 x institutional upper limit of normal

7. If Alkaline Phosphatase = 2.5 x institutional upper limit of normal, then AST and ALT must be = 1.5 x institutional upper limit of normal

15. Patients of childbearing age must not be pregnant and must use established

contraceptive strategies:

1. Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

2. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.

3. Male subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Exclusion Criteria:

1. Pregnant or breast feeding.

2. Serious uncontrolled medical disorder, psychiatric condition or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.

3. Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic), or significant traumatic injury, within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy are exceptions and patients can receive study treatment =1 week after these procedures.

4. History of clinically significant noninfectious interstitial pneumonitis (i.e., limiting activities of daily living or requiring therapeutic intervention), including clinically significant radiation pneumonitis.

5. Residual toxicity from prior anticancer therapy of grade 3 or greater (CTCAE v5.0), with the exception of alopecia.

6. Concurrent use of other anticancer approved or investigational agents.

7. Clinically significant, uncontrolled heart disease and/or recent cardiac event (within

6 months), such as:

1. unstable angina within 6 months prior to screening

2. myocardial infarction within 6 months prior to screening

3. history of documented congestive heart failure (New York Heart Association functional classification III-IV)

4. cardiac arrhythmias not controlled with medication

8. Active autoimmune disease requiring disease modifying therapy (except vitiligo, Grave's, or psoriasis not requiring systemic treatment).

9. Any form of active primary or secondary immunodeficiency.

10. Receiving =10 mg daily prednisone (or equivalent).

11. Prior malignancy (except non-melanoma skin cancers, and the following in situ cancers:

bladder, gastric, colon, cervical/dysplasia endometrial, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period.

12. Active systemic infections requiring intravenous antibiotics.

13. Prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents (other than FDA approved and National Comprehensive Cancer Network [NCCN] recommended systemic therapies).

14. Prisoners or subjects who are involuntarily incarcerated, or who are compulsorily detained for treatment of either a psychiatric or physical illness.

15. Any unresolved grade 2 irAE (except adequately treated endocrine irAE).

16. Any toxicity that led to permanent discontinuation of prior anti-PD-1/PD-L1 immunotherapy.

Related Conditions & MeSH terms

• Advanced Cancer
• Carcinoma
• Carcinoma, Merkel Cell
• Carcinoma, Non-Small-Cell Lung
• Cutaneous Squamous Cell Carcinoma
• Head and Neck Cancer
• Lung Neoplasms
• Melanoma
• Merkel Cell Carcinoma
• Metastatic Cancer
• Non Small Cell Lung Cancer
• Pancreatic Cancer
• Solid Tumor
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Biological:
• MEM-288 Intratumoral Injection
Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNß) and a recombinant chimeric form of CD40-ligand (MEM40).
• Nivolumab
anti-PD1 monoclonal antibody

Locations

Country	Name	City	State
United States	Duke Cancer Institute	Durham	North Carolina
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (3)

Lead Sponsor	Collaborator
Memgen, Inc.	Duke Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory Biomarker Analysis	Analysis of potential associations between biomarker measures and anti-tumor activity, immunogenicity, and immune-activation assessments.	4.5 months
Primary	Part 1 Monotherapy: Maximum Tolerated Dose (MTD)	MTD is defined as the highest dose with = 17% dose limiting toxicity (DLT) rate.	21 days
Primary	Part 1 Monotherapy: Safety and Tolerability assessed by Adverse Events (AEs)	An adverse event (AE) is any untoward medical occurrence in a subject receiving study drug and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended or worsening sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not related to use of the study drug.	4.5 months
Primary	Part 2 MEM-288 plus nivolumab combination: Overall Response Rate (ORR)	ORR measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.	Up to 39 weeks
Secondary	Part 1 Monotherapy: Overall Response Rate (ORR)	ORR measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.	up to 39 weeks
Secondary	Disease Control Rate (DCR)	DCR measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.	up to 39 weeks
Secondary	Duration of Response (DoR)	DoR measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.	up to 39 weeks
Secondary	Progression Free Survival (PFS)	To determine the PFS days post treatment initiation.	up to 39 weeks
Secondary	Overall Survival (OS)	To determine the survival days post treatment initiation.	up to 39 weeks
Secondary	Part 2 MEM-288 plus nivolumab combination: Safety and Tolerability assessed by Adverse Events (AEs)	An adverse event (AE) is any untoward medical occurrence in a subject receiving study drug and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended or worsening sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not related to use of the study drug.	4.5 months